Committed to a translational approach from "patient to patient", the Canceropole GSO brings together nearly 500 scientific and medical research teams from Bordeaux, Limoges, Montpellier, Nîmes, Poitiers and Toulouse around collaborative projects. The Canceropole runs a dynamic cancer research network and offers a coordinated synergy between Institutions, Territories and Disciplines for the benefit of the patient.
The Canceropole GSO has been a a public interest group since August 2007.
A dense scientific and clinical network: 5 universities, Inserm, CNRS. 5 University Hospitals and 3 Comprehensive Cancer Centers. More than 100 technology platforms.
The commitment of 2 Regional Councils: Nouvelle-Aquitaine and Occitanie
Several major industrial members: Bristol Myers Squibb, Pierre Fabre, Roche and Sanofi
A network of partners :
----------1 competitiveness cluster: EuroBioMed - relay for a strong network of biotechnology SMEs
----------1 GIRCI - interregional clinical research group and innovation: SOHO (Sud-Ouest Outre-Mer Hospitalier)
----------2 French blood establishments
Build a scientific animation of Cancer Research in an interregional and transdisciplinary approach that relies on the synergy of skills and equipments of the 2 regions
Strengthen translational research and the links between researchers and clinicians, through scientific events
Support emergence (seed funding), innovation and transfer to the patient
Encourage economic and social promotion and industrial partnerships
in line with the recommendations of the Cancer Plans and the INCa strategy